



September 7, 2017

## **Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for Reproductive Medicine**

PRINCETON, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract presenting data from the Phase 3 SECURE study of its investigational low-dose combined hormonal contraceptive patch (AG200-15) has been selected for an oral presentation during the American Society for Reproductive Medicine (ASRM) Annual Congress being held October 28<sup>th</sup> — November 1<sup>st</sup>, 2017 in San Antonio, TX. The abstract, titled "*Selected Efficacy And Bleeding/Spotting Outcomes From The SECURE Trial: A Phase 3 Study Of AG200-15, An Investigational Weekly Transdermal Contraceptive Patch,*" will be available in the September 2017 issue of *Fertility and Sterility* and online at [www.fertstert.org](http://www.fertstert.org).

The SECURE study evaluated the safety and efficacy of the investigational transdermal contraceptive patch AG200-15, known as Twirla<sup>®</sup>, in a diverse, real-world population of women reflective of current weight trends in the United States. The presentation will include efficacy and safety findings for the overall population and pre-specified body mass index (BMI) categories, in addition to results on the bleeding profile not previously reported.

### **About Agile Therapeutics**

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla<sup>®</sup>, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion<sup>®</sup>, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at [www.agiletherapeutics.com](http://www.agiletherapeutics.com). Follow Agile on social media: [@agilether](https://twitter.com/agilether). The company may occasionally disseminate material, nonpublic information on the company website.

Contact:

Mary Coleman

Agile Therapeutics, Inc.

609-356-1921